报价延迟最少15分钟:2026/07/09 10:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.5963 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.42/-0.38
|
|
企业价值
54.72M
|
| 资产负债 |
|
每股账面净值
0.57
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. |
